Mst Continus (Morphine Sulfate)

Morphine sulfate binds as a full agonist to µ‑opioid receptors in the brain, spinal cord and peripheral nervous system. This binding inhibits the release of pain‑transmitting neurotransmitters, reduces neuronal excitability, and alters pain perception, resulting in analgesia and sedation.

The dose of Mst Continus is individualized. A qualified prescriber determines the appropriate strength, frequency and duration based on the patient’s pain severity, prior opioid exposure, age, organ function and other clinical factors. No generic dosing regimen is provided here.

Safety of morphine sulfate during pregnancy or lactation has not been definitively established. It is generally avoided unless the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives and risks with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Mst Continus. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Both morphine (Mst Continus) and oxycodone are strong µ‑opioid receptor agonists, but they differ in potency, half‑life and formulation options. Morphine is often considered the reference opioid; oxycodone may have a slightly higher oral potency and different side‑effect profiles. Choice depends on patient response, tolerability, and prescriber preference.

Store Mst Continus at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children and unauthorized persons.

Mst Continus is supplied as oral tablets. The tablets should be swallowed whole with a full glass of water and not chewed, crushed or dissolved, unless a prescriber specifically advises an alternative method for patients with swallowing difficulties.

The most serious risks include respiratory depression, severe hypotension, and the development of dependence or addiction. Patients should be monitored for slowed breathing, excessive sedation, unusual dizziness, or any signs of misuse, and should seek immediate medical attention if these occur.

Mst Continus should be avoided in patients with known hypersensitivity to morphine or any opioid, those with severe respiratory depression, uncontrolled asthma, or paralytic ileus. It is also contraindicated in individuals taking monoamine oxidase inhibitors within 14 days or in patients for whom opioid therapy is not appropriate.